Who To Contact
Baptist MD Anderson
Cancer Center
1301 Palm Avenue
Jacksonville, FL 32207
Rebecca Deya, MSN, RN
Research Manager
Baptist MD Anderson Clinical Trials
904.202.7468
rebecca.deya@bmcjax.com
Clinical Trial ID: NCT05446298
Phase II Randomized Open Label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian cancer (PROC)
Status
Open
Conditions
Other
Phases
II
Age Group
Adult
Main Investiagtor
Hand, Lauren
Practice
Gyn
Scope
National
Participating Institutions
Baptist MD Anderson Cancer Center
Nct ID Number
NCT05446298
Secondary Trial ID Number
GOG-3081; ONC-392
Keywords
Treatment